Teleflex Highlights LMA® Gastro™ Airway Study, Which Shows Efficacy for Use in Upper Gastrointestinal Endoscopy

February 22, 2018

Peer-Reviewed Published Study Shows Advantages of LMA® Gastro™ Airway

WAYNE, Pa.--(BUSINESS WIRE)--Feb. 22, 2018-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, has announced that newly published research, in the February 2018 edition of the British Journal of Anesthesia, affirms the LMA® Gastro™ Airway with Cuff Pilot™ Technology yields a high airway insertion success rate and endoscopy success rate when used in patients undergoing upper gastrointestinal endoscopy.[1]

The prospective study, by Nico Terblanche MD, FCA, MMED (Anes) and colleagues, who are independent from Teleflex, sought to determine the efficacy of the LMA® Gastro™ Airway in patients undergoing upper gastrointestinal endoscopy. The study observed 292 patients with ASA physical status classification 1 or 2, and low risk of pulmonary aspiration, who received standardized LMA® Gastro™ Airway insertion during the procedure. The study concluded that the endoscope and LMA® Gastro™ Airway insertion success was 99%, indicating LMA® Gastro™ Airway efficacy.[1]

More than 6.9 million upper endoscopies are performed in the U.S. each year,[2] according to a 2009 study, and the use of moderate-to-deep sedation during endoscopy is a common practice. Respiratory depression from sedative drugs and airway obstruction requiring intervention are known risks associated with these procedures, with studies demonstrating hypoxemia can occur in 11-50% of cases.[3-5] However, today, many of these are undertaken without an airway management device in place.

The LMA® Gastro™ Airway is the first laryngeal mask specifically designed to enable clinicians to proactively manage their patients' airways while facilitating direct endoscopic access via the integrated channel. With the airway in place, clinicians can easily direct an endoscope and provide a patent airway for patient safety, which can facilitate monitoring of end tidal CO_2.

"The LMA® Gastro™ Airway was created in response to a true need for a controlled airway management solution for higher-risk patients undergoing routine upper GI procedures," said Justin McMurray, President and General Manager, Teleflex Anesthesia and Emergency Medicine Division. "As the market leader in supraglottic airways, Teleflex continues to develop innovative airway management devices that help advance clinical practice."

The peer-reviewed paper appears in the February 2018 issue of the *British Journal of Anaesthesia*, which is the oldest and largest independent journal of anesthesia. The study author was Dr. Terblanche, who works in the Department of Anaesthesia and Perioperative Medicine at Royal Hobart Hospital in Tasmania, Australia.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose-driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® - trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

References:

1. Terblanche, NCS, Middleton C. Efficacy of a new dual channel laryngeal mask airway, the LMA® Gastro™ Airway, for upper gastrointestinal endoscopy: a prospective observational study. *British Journal of Anesthesia*. 2018; 120(2):353-360.
2. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology.* 2012;143(5):1179-1187 e1171-1173.
3. Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk factors for hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II patients. *Dig Dis Sci*. 2009;54(5):1035-1040.
4. Cote GA, Hovis RM, Ansstas MA, et al. Incidence of sedation-related complications with Propofol use during advanced

endoscopic procedures. *Clin Gastroenterol Hepatol*. 2010;8(2):137-142.

5. de Paulo GA, Martins FP, Macedo EP, Goncalves ME, Mourao CA, Ferrari AP. Sedation in gastrointestinal endoscopy: a prospective study comparing nonanesthesiologist-administered Propofol and monitored anesthesia care. *Endosc Int Open*. 2015;3(1): E7-E13.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005109/en/

Source: Teleflex Incorporated

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836